The Mayer Professor of Renal Medicine, University of Leicester

My research is focussed on a bench to bedside approach to improving our understanding of the pathogenesis of IgA nephropathy a common global cause of kidney failure. I am the IgA nephropathy Rare Disease Group lead for the UK National Registry of Rare Kidney Diseases (RaDaR) and a member of the steering committee for the International IgA Nephropathy Network. I work closely with pharmaceutical companies interested in new treatments for IgA nephropathy, and am Chief Investigator for a number of international randomised controlled Phase 2 and 3 clinical trials in IgA nephropathy. I was a member of the FDA and American Society of Nephrology Kidney Health Initiative: Identifying Surrogate Endpoints for Clinical Trials in IgA Nephropathy Work group. I am a co-Chair of the UK Glomerulonephritis Clinical Study Group and was IgA nephropathy lead for the recent revision of the KDIGO Clinical Practice Guidelines for Glomerular Diseases.

Back to Organizing committee page